Summary :
Several stocks, including Kotak Mahindra Bank, Persistent Systems, JSW Infrastructure, Adani Ports, HDFC Bank, and ONGC, will remain in focus on key corporate developments. Pharma stocks such as Lupin, Alembic Pharma, Dr. Reddy’s, and Aurobindo Pharma are also in the spotlight following USFDA-related updates. Investors will closely watch these company-specific announcements for potential market impact.
Several companies are expected to remain in focus on Dalal Street following key corporate announcements, regulatory developments, fundraising plans, management changes, acquisitions, and fresh order wins.
Leadership Changes and Corporate Updates
Kotak Mahindra Bank is expected to make the news because of the announcement by its Managing Director and CEO Ashok Vaswani that he will not be seeking reappointment after December 31, 2026, when his term will come to an end. The board of directors has already started the process for appointing a new MD & CEO.
ONGC has appointed Anupam Agarwal as its new Chief Financial Officer (CFO). At the same time, NIBE has seen its CEO Prakash Hari Khose resign from the post. Similarly, CFO Nutan Gaba Patwari has also resigned from Home First Finance Company India. IIFL Finance has appointed Vikas Jain as its new CFO following the move of Kapish Jain to a different position in the company.
Acquisitions, Fundraising and Strategic Deals
Persistent Systems made one of the largest announcements of the day when it approved the takeover of Nagarro SE, based out of Germany, through its subsidiary. Apart from that, the company has entered into a strategic service agreement worth more than $650 million with an American technology giant.
Torrent Power completed the takeover of Nabha Power from L&T Power Development for ₹3,632.35 crore.
JSW Infrastructure completed the issuance of equity shares for a total amount of ₹7,502.69 crore through QIP. PTC Industries made an announcement of raising funds for up to ₹1,800 crore. The board of IIFL Finance has approved raising funds for up to ₹10,000 crore through various securities.
Pharma Stocks in Focus
Various pharmaceutical companies provided information on regulatory affairs.
Lupin has obtained tentative approval from US FDA for Enzalutamide Tablets that is indicated in the treatment of prostate cancer. Alembic Pharmaceuticals has obtained final US FDA approval for Oseltamivir Phosphate Oral Suspension whereas Jubilant Pharmova has received tentative approval for Pantoprazole Sodium Delayed-Release Oral Suspension.
Aurobindo Pharma successfully underwent US FDA inspection of its Andhra Pradesh plant, resulting in two observations being raised. Dr Reddy's Laboratories also successfully conducted pre-license US FDA inspection of its biologics manufacturing plant, and this resulted in seven observations on Form 483.
Indoco Remedies has achieved EU GMP certification of its Goa manufacturing plant by Malta Medicines Authority.
Orders, Ratings and Business Expansion
BEML has got another export deal amounting to around $5.35 million from the Middle East, thereby taking its overall contract size to nearly $41.73 million.
Transrail Lighting has got some fresh international orders amounting to ₹459 crore, thereby taking its orders for the year to ₹1,034 crore. Ashoka Buildcon has got a highway construction deal worth $35.42 million in Guyana.
Adani Green Energy has commissioned a 150 MW solar power plant at Khavda in Gujarat, which has taken its total operating renewable energy capacity to almost 20 GW.
Adani Ports and Special Economic Zone has got a major credit rating upgrade from S&P Global Ratings with its long-term issuer rating being raised to BBB, which puts it on par with India's sovereign rating.
Other Stocks to Watch
KEC International returned to eligibility for Power Grid tenders after the exclusion order was revoked. Hexaware Technologies became an Anthropic-authorised reseller for Amazon Bedrock, enabling it to offer Claude AI models to enterprise customers globally.
Waaree Energies clarified that the US Customs determination had no adverse impact on its business operations or exports to the United States. Meanwhile, HDFC Bank remained in focus after an independent legal review found no evidence supporting concerns raised by former Chairman Atanu Chakraborty, who later disputed the findings.
